Active Biotech AB (publ), a biotechnology company, together with its subsidiaries, develops drugs for the treatment of neurodegenerative, inflammatory, and cancer diseases in Sweden.
+ 1 more risk
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Active Biotech's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BTPC's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: BTPC underperformed the German Biotechs industry which returned 5.5% over the past year.
Return vs Market: BTPC underperformed the German Market which returned 8.3% over the past year.
Price Volatility Vs. Market
How volatile is Active Biotech's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Active Biotech undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BTPC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate BTPC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: BTPC is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: BTPC is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BTPC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BTPC is overvalued based on its PB Ratio (8.2x) compared to the DE Biotechs industry average (3.5x).
How is Active Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Active Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Active Biotech's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Active Biotech competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Active Biotech performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BTPC is currently unprofitable.
Growing Profit Margin: BTPC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BTPC is unprofitable, but has reduced losses over the past 5 years at a rate of 37.9% per year.
Accelerating Growth: Unable to compare BTPC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BTPC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: BTPC has a negative Return on Equity (-63.38%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Active Biotech's financial position?
Financial Position Analysis
Short Term Liabilities: BTPC's short term assets (SEK63.8M) exceed its short term liabilities (SEK11.2M).
Long Term Liabilities: BTPC's short term assets (SEK63.8M) exceed its long term liabilities (SEK2.0M).
Debt to Equity History and Analysis
Debt Level: BTPC is debt free.
Reducing Debt: BTPC has no debt compared to 5 years ago when its debt to equity ratio was 55.7%.
Inventory Level: BTPC has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if BTPC's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BTPC has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BTPC has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 36% each year.
What is Active Biotech's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate BTPC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate BTPC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BTPC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BTPC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BTPC's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Helén Tuvesson (57yo)
Ms. Helén Tuvesson is President and Chief Executive Officer of Active Biotech AB ("Active Biotech"). She has a PhD in medical science from Lund University. She has extensive experience in drug development ...
CEO Compensation Analysis
Compensation vs Market: Helén's total compensation ($USD268.88K) is below average for companies of similar size in the German market ($USD414.81K).
Compensation vs Earnings: Helén's compensation has increased whilst the company is unprofitable.
|Independent Director||8.8yrs||kr125.00k||1.96% SEK822.0k|
|Director||0.8yrs||no data||no data|
|Chairman of the Board||0.8yrs||no data||no data|
|Independent Director||20.1yrs||kr125.00k||0.027% SEK11.2k|
Experienced Board: BTPC's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.6%.
Active Biotech AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: Active Biotech AB (publ)
- Ticker: BTPC
- Exchange: DB
- Founded: 1982
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr442.971m
- Listing Market Cap: kr41.891m
- Shares outstanding: 145.24m
- Website: https://www.activebiotech.com
Number of Employees
- Active Biotech AB (publ)
- Scheelevägen 22
- 223 63
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ACTI||OM (OMX Nordic Exchange Stockholm)||Yes||Ordinary Shares||SE||SEK||Jun 1995|
|0GQU||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||SEK||Jun 1995|
|BTPC||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Jun 1995|
|ACTIs||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||SEK||Jun 1995|
Active Biotech AB (publ), a biotechnology company, together with its subsidiaries, develops drugs for the treatment of neurodegenerative, inflammatory, and cancer diseases in Sweden. The company is involved in developing ANYARA, a tumor targeting superantigen to kill tumor cell; Tasquinimod, an oral immunomodulatory compound for the treatment of multiple myeloma, a form of blood cancer; and SILC, an S100A9 inhibition by low molecular weight compounds for the treatment of cancer. It is also developing Laquinimod, an oral immunomodulatory drug that has completed Phase II clinical trial for Huntington’s disease; and Paquinimod, an oral immunomodulatory compound that has completed Phase I clinical trial for the treatment of systemic lupus erythematosus and systemic sclerosis. The company has a partnership agreement with NeoTX Therapeutics Ltd. for the development of naptumumab. Active Biotech AB (publ) was incorporated in 1982 and is headquartered in Lund, Sweden.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/25 21:37|
|End of Day Share Price||2020/02/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.